UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) February 9, 2012

RTI BIOLOGICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Registrant’s telephone number, including area code: (386) 418-8888

not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) Compensatory Arrangements of Certain Officers

2012 Salaries and Bonus Targets. On February 9, 2012, the Compensation Committee of the Board of Directors of RTI Biologics, Inc. (the “Company”) approved 2012 salaries and a bonus plan (the “2012 Bonus Plan”) providing for the payment of cash bonuses based on the Company’s operating results for the 2012 calendar year. The 2012 Bonus Plan sets target bonus amounts and performance criteria for executive officers. The performance criteria include pretax income, operating cash flow, and revenues. As in the past, the Compensation Committee retains discretion to take other factors into account in determining bonuses and to award no bonuses even if performance criteria are met.

The table below sets forth the 2012 salaries and bonus targets (expressed as a percentage of salary) for the Company’s chief executive officer, principal financial officer and three most highly compensated executive officers other than the chief executive officer and principal financial officer:

Stock Option and Restricted Stock Grants. On February 9, 2012, the Compensation Committee approved awards of stock options and restricted stock to certain executive officers of the Company pursuant to the 2010 Equity Incentive Plan (the “Plan”). The options are exercisable for $4.02 per share (the closing price on the date of grant) and will vest in five equal annual installments beginning on the first anniversary of the date of grant. The restricted stock, valued at $4.02 (the closing price on the date of grant), will vest in three equal annual installments beginning on the first anniversary of the date of grant. Both grants are subject to accelerated vesting upon the occurrence of a “Change of Control” (as defined in the Plan).

The table below sets forth the number of stock options and restricted stock awarded to the Company’s named executive officers:

In addition, on February 9, 2012, the Compensation Committee approved an award of 12,438 shares of restricted stock options to each member of the Company’s Board of Directors pursuant to the Plan. The restricted stock, valued at $4.02 (the closing price on the date of grant), will vest on the first anniversary of the date of grant, subject to accelerated vesting upon the occurrence of a “Change of Control” (as defined in the Plan).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.